Sunday, December 16, 2012

Poll: Top Nephrology-Related Stories of 2012

We would appreciate your vote for the top nephrology-related stories of 2012. Take a second and click any of the answers on the right hand side of the screen that you think should be considered in the Top 10 stories. We will give the results of the poll shortly after the poll closes on Friday December 21st.
at

3 comments:

  1. Graham AbraDecember 17, 2012 at 8:48 PM

    Added another contender... The FDA Innovation Pathway 2.0, a more streamlined and efficient FDA approval process which chose three devices focused on solving problems in the care of patients with ESRD.

    ReplyDelete
  2. Graham AbraDecember 17, 2012 at 8:50 PM

    Darn, looks like we can't edit the poll now that it's opened. Comment here if you want vote for the FDA Innovation Pathway 2.0 :)

    ReplyDelete
  3. Kidney_BoyDecember 17, 2012 at 11:47 PM

    The only story that should get any votes is Temp 3:4. Major break through which, unless turns out to be a type 1 error, will rank with ACEi and EPO as standout pharmaceutical moments in nephrology. The tolvaptan story will be on your list of stories of the decade in December 2019, unless you've graduated by then.

    ReplyDelete

Renal Fellow Network encourages comments and discussion regarding the posts. Do not post any comments that are commercial or advertising in nature. Posts will be deleted if commercial or advertising comments are made. Internet users commenting on the Renal Fellow Network must post information which is true and correct to their knowledge. Sources to health/medical claims must be provided when relevant. Moderators reserve the right to erase, without notification, any comment they would judge inappropriate.